The effect of zinc sulfate and folic acid on endocrine indices, CRP and lipid profile in women with polycystic ovary syndrome

Phase 3

• Conditions: Polycystic ovary syndrome.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT20200610047715N1
• Lead Sponsor: Rafsanjan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

Oligoovulation or / and anovulation
Clinical symptoms (Ferriman-Gallwey score=6 or Acne or Seborrhoeic) or biochemical hyperandrogenism
Evidence of polycystic ovaries on ultrasound

Exclusion Criteria

Hyperprolactinoma
Thyroid disease
Cardiovascular diseases
Kidney-liver and neoplastic diseases
Type 2 diabetes
Pregnancy or breastfeeding
Absorption disorders
Use of drugs such as anti-diabetic drugs, anti-obesity drugs, diuretics, OCP, steroid and hormonal drugs (at least 3-6 months) and drugs that interfere with folic acid (perimetamine, aspirin, carbamazepine, chloramphenicol, chlorothiazide, conjugated estrogens, forge , Hydrochlorothiazide, Methotrexate, Phenytoin, Phenobarbital, Sulfamethoxazole, Salicylate)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
FBS. Timepoint: 8 weeks after taking the drug. Method of measurement: BT4500.;Dehydroepiandrosterone sulfate. Timepoint: 8 weeks after taking the drug. Method of measurement: ELISA reader.;Testosterone. Timepoint: 8 weeks after taking the drug. Method of measurement: ELISA reader.